Achillion Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: New Haven CT United States (1998)
Status: Acquired by Alexion (2019) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial
2002
NCT00034359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Achillion Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Communicable Diseases (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulonephritis, Membranoproliferative (Phase 2)

Hemoglobinuria (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 2)

Liver Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 23
  • # of Trial APIs: 19